Highest-materiality recent filing
Immuneering reports 17.3-month median OS in Phase 2a pancreatic trial of atebimetinib
In 55-patient ITT population, mOS 17.3 months (cutoff Apr 24, 2026) vs 8.5 months standard of care.
Immuneering Q1 net loss $13.5M; cash $198.6M; Phase 3 pancreatic trial recruiting; ASCO data June 1
Q1 2026 net loss $13.5M ($0.21 per share) vs $15.0M ($0.42 per share) in Q1 2025.
Immuneering: FY2025 net loss $56M, cash $217M, 64% OS at 12 months in pancreatic cancer
Net loss for FY2025 was $56.0M ($1.27/share), down from $61.0M ($2.04/share) in 2024.
Immuneering reports 64% OS at 12 months in Phase 2a pancreatic cancer trial; median OS not reached
64% OS at 12 months (SOC 35%) in 34 first-line pancreatic cancer patients at 320 mg atebimetinib + mGnP; median OS not reached.
Immuneering Q3: 86% 9-month OS in pancreatic cancer; raised $225M; cash into 2029
Reported 86% overall survival at 9 months in first-line pancreatic cancer with atebimetinib + mGnP.
Immuneering prices $175M public offering; Sanofi invests $25M in concurrent private placement
Public offering of 18,959,914 shares at $9.23/share; expected gross ~$175M; net proceeds ~$164.1M.
Sanofi subsidiary Aventis agrees to purchase $25M in stock at public offering price; closing contingent on $75M+ public offering by Sept 26, 2025.
Immuneering raises $25M in private placement at $3.95/unit, warrants at $5.50
$25M gross proceeds from 6.33M shares (or pre-funded warrants) and 2.85M warrants at $5.50.
Immuneering reports Q2 net loss $14.4M; highlights 94% OS at 6 months in pancreatic cancer trial
Net loss of $14.4M ($0.40/share) vs $14.1M ($0.47/share) in Q2 2024; cash $26.4M as of June 30.
Immuneering reports interim Phase 2a data: 39% ORR, 81% DCR in first-line pancreatic cancer
As of May 26, 2025 cutoff: 1 CR, 13 PR (4 pending confirmation), 15 SD among 36 evaluable patients; DCR 81%, ORR 39%.
Immuneering reports Q1 2025 results: net loss $15M, positive IMM-1-104 data, CMO named
Net loss $15.0M ($0.42/sh) vs $14.3M ($0.49/sh) in Q1 2024; R&D expenses $11.5M.
Immuneering reports positive Phase 2a data for IMM-1-104 in pancreatic cancer; cash runway into 2026
Phase 2a data: IMM-1-104 + mGnP showed 43% ORR, 86% DCR; + mFFX showed 50% ORR vs historic 23% and 32%.
Immuneering reports 50% ORR in Phase 2a of IMM-1-104/mFFX; raises $13.7M via ATM
As of Jan 6, 2025, 3 of 6 evaluable patients achieved partial response, 3 stable disease; 50% ORR per RECIST.
Immuneering reports 43% ORR in first-line pancreatic combo; plans new trials in 2025
IMM-1-104 + mGnP in 1L pancreatic: 1 complete response, 2 partial response (43% ORR), 86% DCR among 7 evaluable patients.
Immuneering Q3 net loss $14.6M; positive initial Phase 2a data for IMM-1-104
Net loss $14.6M ($0.49/share) vs $12.6M ($0.43) in Q3 2023; cash $50.7M.
Immuneering reports 40% ORR, 80% DCR from IMM-1-104 combo in pancreatic cancer
First patient had complete response; second unconfirmed partial; third/fourth stable disease; fifth equivocal progressive disease.
Net loss $14.1M ($0.47/share) vs $12.2M ($0.43) in Q2 2023.
Immuneering reprices underwater employee stock options to $3.01 with retention restriction
Repricing applies to options with exercise price >$3.01 held by employees and certain service providers; excludes CEO, CSO, and non-employee directors.
Immuneering reports Q1 net loss $14.3M; Phase 2a data for IMM-1-104 expected in 2024
Net loss $14.3M ($0.49/share) vs $13.6M ($0.51) Q1 2023; R&D expense $11.2M up from $10.2M.
First patient dosed in Phase 2a of IMM-1-104; ~150 patients planned across 5 arms (monotherapy and combination).
Immuneering reports $85.7M cash, net loss $53.5M in 2023; trial milestones ahead
Cash, cash equivalents and marketable securities $85.7M as of Dec 31, 2023; cash runway into 2H 2025.
On March 11, 2024, the Board of Directors of Immuneering Corporation (“we,” “our” and “us”) appointed Thomas J. Schall, Ph.D. to serve as a member of our Board of Directors as a Class I Director.
Max materiality 0.85 · Median 0.75 · Most common event other_material